These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32987955)

  • 1. Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma.
    Stragliotto G; Pantalone MR; Rahbar A; Söderberg-Nauclér C
    Microorganisms; 2020 Sep; 8(10):. PubMed ID: 32987955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma.
    Pantalone MR; Rahbar A; Söderberg-Naucler C; Stragliotto G
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.
    Stragliotto G; Rahbar A; Solberg NW; Lilja A; Taher C; Orrego A; Bjurman B; Tammik C; Skarman P; Peredo I; Söderberg-Nauclér C
    Int J Cancer; 2013 Sep; 133(5):1204-13. PubMed ID: 23404447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience.
    Peng C; Wang J; Tanksley JP; Mobley BC; Ayers GD; Moots PL; Clark SW
    Mol Clin Oncol; 2016 Feb; 4(2):154-158. PubMed ID: 26893852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma.
    Hossain JA; Latif MA; Ystaas LAR; Ninzima S; Riecken K; Muller A; Azuaje F; Joseph JV; Talasila KM; Ghimire J; Fehse B; Bjerkvig R; Miletic H
    Neuro Oncol; 2019 Jul; 21(7):890-900. PubMed ID: 30958558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
    Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
    N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
    Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
    Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
    Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
    Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
    Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
    Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Viral Connection to Glioblastoma.
    McFaline-Figueroa JR; Wen PY
    Curr Infect Dis Rep; 2017 Feb; 19(2):5. PubMed ID: 28233187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
    Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
    Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus and glioblastoma: a review of evidence for their association and indications for testing and treatment.
    Solomon IH; Ramkissoon SH; Milner DA; Folkerth RD
    J Neuropathol Exp Neurol; 2014 Nov; 73(11):994-8. PubMed ID: 25289896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
    Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
    Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
    Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation.
    Leone F; Akl A; Giral M; Dantal J; Blancho G; Soulillou JP; Cantarovich D
    Transpl Int; 2010 Sep; 23(9):897-906. PubMed ID: 20230540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.
    Kimberlin DW; Acosta EP; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud GA; Lakeman FD; Whitley RJ;
    J Infect Dis; 2008 Mar; 197(6):836-45. PubMed ID: 18279073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.